News

Commercial, medical and outcomes research teams in biopharma and life sciences companies will now be able to leverage an offering that combines IMS Health’s powerful Real-World Evidence (RWE)

As previously reported, oral treatment with Optina (low-dose danazol) has been shown to be safe and confer significant improvements in visual acuity (VA) and reductions in central retinal

The application covers InVivo’s investigational Neuro-Spinal Scaffold, which is currently being studied in a pilot clinical trial and has been successfully implanted in three patients. Also covered is

The trial enrolled patients across seven U.S. sites and is evaluating two constructs: a monovalent (gD) vaccine and a bivalent (gD + UL46) vaccine, each formulated with Vical’s

The new TCR candidates are directed against the HPV type 16 E6 oncoprotein incorporating gene editing and lentiviral technologies to efficiently modify certain genes to improve T cell

The new intravenous antiplatelet agent adds to the company’s commercial offerings in the cardiac cath lab. The company intends to introduce kengreal, which is the first and only

L-DOS47 is the company’s first immunoconjugate-based drug candidate being developed based upon its new DOS47 technology, which is designed to use an innovative approach to modify the microenvironmental

The company said that this marks the first FDA approved starting material from its Chinese subsidiary ANP, and signifies that this facility has been qualified by the FDA.

The move has been facilitated by the start of a collaboration between Benitec and ReNeuron, a UK-based stem cell therapeutics firm. The new program will use Benitec’s ddRNAi